Search - tctmd.com

Displaying 1 - 20 of 67

Sort: Relevancy | Date

Presentation TCT 2025

Mitigating Stroke Risk in TAVR: Role of SENTINEL Embolic Protection

Presenter: Alexandra J. Lansky

October 28, 2025

Presentation TCT 2025

Clinical Path SERRA-I Early Feasibility Study

Presenter: Alexandra J. Lansky

October 26, 2025

Presentation NY Valves 2025

Stroke and Cerebral Embolic Protection Devices in Contemporary TAVR Practice

Presenter: Alexandra J. Lansky

June 26, 2025

Presentation NY Valves 2025

Untangling The Knot: Defining Appropriate Clinical Trial Endpoints and the Path Forward

Presenter: Alexandra J. Lansky

June 25, 2025

Presentation TCT 2024

Variations in New Clinical Trial Designs for Emerging CEP Devices

Presenter: Alexandra Lansky

October 30, 2024

Presentation TCT 2024

Academic Promotions – How Do you Do it Successfully

Presenter: Alexandra Lansky

October 29, 2024

Presentation TCT 2024

Interpreting the PEERLESS Trial Through the Statistical Lens

Presenter: Alexandra Lansky

October 29, 2024

Presentation TCT 2024

Importance of DW-MRI in Cerebral Embolic Protection Trials

Presenter: Alexandra Lansky

October 28, 2024

Presentation TCT 2024

Final Results of the Novel Healing-Targeted DES With Synchronized Antiproliferative Drug Delivery to Target Smooth Muscle Cell Proliferation After DES Implantation in Coronary Artery Disease: 5-Year Results of the PIONEER III Trial

Presenter: Alexandra Lansky

October 27, 2024

Presentation NY Valves 2024

Modern Era Clinical Trial Strategies For Cerebral Embolic Protection Devices

Presenter: Alexandra J. Lansky

June 05, 2024

Presentation TCT 2023

Beyond Support: Impella® as a Risk Modifier

Presenter: Alexandra Lansky

October 24, 2023

Presentation TCT 2022

For Most Patients, Only Spontaneous MI Is Relevant

Presenter: Alexandra J. Lansky

September 18, 2022

Presentation TCT 2022

TARGET All Comers Trial 5-year Outcomes and Substudy Analysis

Presenter: Alexandra Lansky

September 18, 2022

Presentation TCT 2022

Regulatory Pathways and Clinical Trials After PROTECTED TAVR

Presenter: Alexandra J. Lansky

September 17, 2022

Presentation TVT 2022

Clinical Trial Pathways and Study Designs: Embolic Capture vs Deflection Devices

Presenter: Alexandra Lansky

June 10, 2022

Presentation ACC 2022

A Randomized Trial To Confirm The Safety And Effectiveness Of Chocolate Touch Paclitaxel Coated PTA Balloon Catheter In Above The Knee Lesions

Presenter: Alexandra Lansky

April 04, 2022

Presentation TCT 2021

TARGET AC 4-year Results & Deep Dive in Diabetes Subgroup

Presenter: Alexandra Lansky

November 06, 2021

Presentation TCT 2021

Disrupt CAD Pooled Female vs Male Analysis

Presenter: Alexandra Lansky

November 05, 2021

Presentation TCT 2020

TCT 181: A Propensity Matched Analysis of Impella use From a Large-Scale Claims Data: Influence of Analytic Methodology on Clinical Outcomes

Presenter: Alexandra Lansky

October 14, 2020

Presentation CIT 2019

Cerebral Protection in TAVR

Presenter: Alexandra Lansky

March 28, 2019

Advertisement

Mitigating Stroke Risk in TAVR: Role of SENTINEL Embolic Protection

Clinical Path SERRA-I Early Feasibility Study

Stroke and Cerebral Embolic Protection Devices in Contemporary TAVR Practice

Untangling The Knot: Defining Appropriate Clinical Trial Endpoints and the Path Forward

Variations in New Clinical Trial Designs for Emerging CEP Devices

Academic Promotions – How Do you Do it Successfully

Interpreting the PEERLESS Trial Through the Statistical Lens

Importance of DW-MRI in Cerebral Embolic Protection Trials

Final Results of the Novel Healing-Targeted DES With Synchronized Antiproliferative Drug Delivery to Target Smooth Muscle Cell Proliferation After DES Implantation in Coronary Artery Disease: 5-Year Results of the PIONEER III Trial

Modern Era Clinical Trial Strategies For Cerebral Embolic Protection Devices

Beyond Support: Impella® as a Risk Modifier

For Most Patients, Only Spontaneous MI Is Relevant

TARGET All Comers Trial 5-year Outcomes and Substudy Analysis

Regulatory Pathways and Clinical Trials After PROTECTED TAVR

Clinical Trial Pathways and Study Designs: Embolic Capture vs Deflection Devices

A Randomized Trial To Confirm The Safety And Effectiveness Of Chocolate Touch Paclitaxel Coated PTA Balloon Catheter In Above The Knee Lesions

TARGET AC 4-year Results & Deep Dive in Diabetes Subgroup

Disrupt CAD Pooled Female vs Male Analysis

TCT 181: A Propensity Matched Analysis of Impella use From a Large-Scale Claims Data: Influence of Analytic Methodology on Clinical Outcomes

Cerebral Protection in TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content